About Us
Accelerating Drug Discovery.
Our platform combines our unique Organ-on-a-Chip technology, multicellular 3D disease model development, and Artificial Intelligence (AI) to provide spatiotemporal profiling and analysis of drug testing and treatment at a cellular level.
Our microfluidic-based Organ-on-a-Chip technology recapitulates the multicellular microenvironment of the organ, incorporating vascularization, biomechanical structure and forces, and paracrine signaling experienced in vivo, providing an excellent in vitro model suitable for drug discovery.
Downstream morphological, secretory, and multi-omics profiling of these complex organ models using AI and machine learning analysis, allows the development of multiplexed profiles of different cellular populations, permitting the detection of subtle biologically relevant responses and phenotypes.
Team
XIN XIE, PHD
Cofounder
CEO
HERMIONE HE
Cofounder Strategy & Investor Relations
XIAOHUA QIAN, PHD
Engineering & Product Development
HAIQING BAI, PHD
Biology & Preclinical Development
KRISTEN OLSON, PHD
Sr. Principal
Scientist
PAIGE GILBRIDE
Sr Res
Assoc
ALYSSA FANELLI
Scientist II
Lab Admin
HARDEEP SINGH
Lead
Engineer
THOMAS MARSHALL
Mechanical
Engineer
JINGZHE MA, PHD
Sr Scientist
AI
JOLENE YUAN, MS
Assoc Scientist
Imaging
JENNA MCCORMACK
Research
Associate
XUHAI (JACK) HUANG
Senior
Engineer
HONG BAO
Accountant
JUSTIN SOK
Engineer
Scientific Advisory Board
YU SHRIKE ZHANG, PHD
Professor at Harvard Medical School
POLINA GOLLAND,
PHD
Professor
at MIT
CAROL LIVERMORE, PHD
Professor at
Northeastern
Interested in joining our team?
Complexity & Scalability
In addition to providing biologically relevant complexity, our device and platform are designed for scalability, allowing high-throughput screening and lab automation compatibility, to meet the efficiency needs of drug discovery and development. At Xellar Biosystems, we excel at complexity and scalability to accelerate the world of drug discovery and development
